Fighting colorectal cancer: Molecular epidemiology differences among Ashkenazi and Sephardic Jews and Palestinians

H. Darwish; I. E. Trejo; I. Shapira; S. Oweineh; M. Sughayer; L. Baron; E. Aljadeff; M. Silbermann; W. Sweidan; D. Zilberg; Z. Halpern; H. Hibshoosh; N. Arber

doi:10.1093/annonc/mdf230

Fighting colorectal cancer: Molecular epidemiology differences among Ashkenazi and Sephardic Jews and Palestinians

H. Darwish, I. E. Trejo, I. Shapira, S. Oweineh, M. Sughayer, L. Baron, E. Aljadeff, M. Silbermann, W. Sweidan, D. Zilberg, Z. Halpern, H. Hibshoosh, N. Arber^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

Background: To evaluate and compare differences in the molecular genetics among high-risk (Ashkenazi Jews), intermediate-risk (Sephardic Jews) and low-risk (Palestinians) groups for colorectal cancer who live in the same geographical region. Patients and methods: The 1995-1996 records from the Tel Aviv Medical Center and Muqased hospital (East Jerusalem) randomly identified patients with colorectal cancer. There were 25 patients from each ethnic group. Epidemiological data were obtained from interviews with the patients and from their hospital charts. The levels of cyclin D1, β-catenine, p27, p53, Ki-67 and Her-2/neu proteins were determined by immunohistochemistry. The main outcome measures were the association between gene expression and colorectal incidence in the different ethnic groups. Results: Ashkenazi Jews have the highest rate of colorectal cancer, and are diagnosed at an early stage compared with Palestinians (72% and 33% of the cases are in Dukes' A and B, respectively), and, hence, this may explain the better 5-year survival rate among this group. Sephardic Jews are diagnosed at a more advanced stage, the tumors are poorly differentiated and they lack p27. Palestinians have significantly higher cyclin D1 levels. There was a statistically significant inverse correlation between the expression of β-catenine and cyclin D1, as well as p53 and p27 (P<0.05). Conclusions: Increased expression of cyclin D1, p53, Ki-67, β-catenine and Her-2/neu, and decreased expression of p27 may be important events in the three ethnic groups with colorectal cancer. The lower mortality rate among Ashkenazi Jews may be partially explained by their better molecular biology profile.

Original language	English
Pages (from-to)	1497-1501
Number of pages	5
Journal	Annals of Oncology
Volume	13
Issue number	9
DOIs	https://doi.org/10.1093/annonc/mdf230
State	Published - Sep 2002
Externally published	Yes

Keywords

Ashkenazi Jews
Colorectal cancer
Molecular epidemiology
Palestinians
Sephardic Jews

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdf230

Cite this

Darwish, H., Trejo, I. E., Shapira, I., Oweineh, S., Sughayer, M., Baron, L., Aljadeff, E., Silbermann, M., Sweidan, W., Zilberg, D., Halpern, Z., Hibshoosh, H., & Arber, N. (2002). Fighting colorectal cancer: Molecular epidemiology differences among Ashkenazi and Sephardic Jews and Palestinians. Annals of Oncology, 13(9), 1497-1501. https://doi.org/10.1093/annonc/mdf230

@article{979d5e55fe0242349914903006d214d6,

title = "Fighting colorectal cancer: Molecular epidemiology differences among Ashkenazi and Sephardic Jews and Palestinians",

abstract = "Background: To evaluate and compare differences in the molecular genetics among high-risk (Ashkenazi Jews), intermediate-risk (Sephardic Jews) and low-risk (Palestinians) groups for colorectal cancer who live in the same geographical region. Patients and methods: The 1995-1996 records from the Tel Aviv Medical Center and Muqased hospital (East Jerusalem) randomly identified patients with colorectal cancer. There were 25 patients from each ethnic group. Epidemiological data were obtained from interviews with the patients and from their hospital charts. The levels of cyclin D1, β-catenine, p27, p53, Ki-67 and Her-2/neu proteins were determined by immunohistochemistry. The main outcome measures were the association between gene expression and colorectal incidence in the different ethnic groups. Results: Ashkenazi Jews have the highest rate of colorectal cancer, and are diagnosed at an early stage compared with Palestinians (72% and 33% of the cases are in Dukes' A and B, respectively), and, hence, this may explain the better 5-year survival rate among this group. Sephardic Jews are diagnosed at a more advanced stage, the tumors are poorly differentiated and they lack p27. Palestinians have significantly higher cyclin D1 levels. There was a statistically significant inverse correlation between the expression of β-catenine and cyclin D1, as well as p53 and p27 (P<0.05). Conclusions: Increased expression of cyclin D1, p53, Ki-67, β-catenine and Her-2/neu, and decreased expression of p27 may be important events in the three ethnic groups with colorectal cancer. The lower mortality rate among Ashkenazi Jews may be partially explained by their better molecular biology profile.",

keywords = "Ashkenazi Jews, Colorectal cancer, Molecular epidemiology, Palestinians, Sephardic Jews",

author = "H. Darwish and Trejo, {I. E.} and I. Shapira and S. Oweineh and M. Sughayer and L. Baron and E. Aljadeff and M. Silbermann and W. Sweidan and D. Zilberg and Z. Halpern and H. Hibshoosh and N. Arber",

note = "Funding Information: The authors are indebted to Dr Wendy Atkin and Dr Bernard Levin for their invaluable professional and scientific contribution, and to Mrs Heather Rockman for editorial assistance. Funding from the Middle E ast Cancer Consortium (to H.D. and N.A.), and the Israel Cancer Association (to N.A.) supported this study.",

year = "2002",

month = sep,

doi = "10.1093/annonc/mdf230",

language = "英语",

volume = "13",

pages = "1497--1501",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "9",

}

Darwish, H, Trejo, IE, Shapira, I, Oweineh, S, Sughayer, M, Baron, L, Aljadeff, E, Silbermann, M, Sweidan, W, Zilberg, D, Halpern, Z, Hibshoosh, H & Arber, N 2002, 'Fighting colorectal cancer: Molecular epidemiology differences among Ashkenazi and Sephardic Jews and Palestinians', Annals of Oncology, vol. 13, no. 9, pp. 1497-1501. https://doi.org/10.1093/annonc/mdf230

TY - JOUR

T1 - Fighting colorectal cancer

T2 - Molecular epidemiology differences among Ashkenazi and Sephardic Jews and Palestinians

AU - Darwish, H.

AU - Trejo, I. E.

AU - Shapira, I.

AU - Oweineh, S.

AU - Sughayer, M.

AU - Baron, L.

AU - Aljadeff, E.

AU - Silbermann, M.

AU - Sweidan, W.

AU - Zilberg, D.

AU - Halpern, Z.

AU - Hibshoosh, H.

AU - Arber, N.

N1 - Funding Information: The authors are indebted to Dr Wendy Atkin and Dr Bernard Levin for their invaluable professional and scientific contribution, and to Mrs Heather Rockman for editorial assistance. Funding from the Middle E ast Cancer Consortium (to H.D. and N.A.), and the Israel Cancer Association (to N.A.) supported this study.

PY - 2002/9

Y1 - 2002/9

N2 - Background: To evaluate and compare differences in the molecular genetics among high-risk (Ashkenazi Jews), intermediate-risk (Sephardic Jews) and low-risk (Palestinians) groups for colorectal cancer who live in the same geographical region. Patients and methods: The 1995-1996 records from the Tel Aviv Medical Center and Muqased hospital (East Jerusalem) randomly identified patients with colorectal cancer. There were 25 patients from each ethnic group. Epidemiological data were obtained from interviews with the patients and from their hospital charts. The levels of cyclin D1, β-catenine, p27, p53, Ki-67 and Her-2/neu proteins were determined by immunohistochemistry. The main outcome measures were the association between gene expression and colorectal incidence in the different ethnic groups. Results: Ashkenazi Jews have the highest rate of colorectal cancer, and are diagnosed at an early stage compared with Palestinians (72% and 33% of the cases are in Dukes' A and B, respectively), and, hence, this may explain the better 5-year survival rate among this group. Sephardic Jews are diagnosed at a more advanced stage, the tumors are poorly differentiated and they lack p27. Palestinians have significantly higher cyclin D1 levels. There was a statistically significant inverse correlation between the expression of β-catenine and cyclin D1, as well as p53 and p27 (P<0.05). Conclusions: Increased expression of cyclin D1, p53, Ki-67, β-catenine and Her-2/neu, and decreased expression of p27 may be important events in the three ethnic groups with colorectal cancer. The lower mortality rate among Ashkenazi Jews may be partially explained by their better molecular biology profile.

AB - Background: To evaluate and compare differences in the molecular genetics among high-risk (Ashkenazi Jews), intermediate-risk (Sephardic Jews) and low-risk (Palestinians) groups for colorectal cancer who live in the same geographical region. Patients and methods: The 1995-1996 records from the Tel Aviv Medical Center and Muqased hospital (East Jerusalem) randomly identified patients with colorectal cancer. There were 25 patients from each ethnic group. Epidemiological data were obtained from interviews with the patients and from their hospital charts. The levels of cyclin D1, β-catenine, p27, p53, Ki-67 and Her-2/neu proteins were determined by immunohistochemistry. The main outcome measures were the association between gene expression and colorectal incidence in the different ethnic groups. Results: Ashkenazi Jews have the highest rate of colorectal cancer, and are diagnosed at an early stage compared with Palestinians (72% and 33% of the cases are in Dukes' A and B, respectively), and, hence, this may explain the better 5-year survival rate among this group. Sephardic Jews are diagnosed at a more advanced stage, the tumors are poorly differentiated and they lack p27. Palestinians have significantly higher cyclin D1 levels. There was a statistically significant inverse correlation between the expression of β-catenine and cyclin D1, as well as p53 and p27 (P<0.05). Conclusions: Increased expression of cyclin D1, p53, Ki-67, β-catenine and Her-2/neu, and decreased expression of p27 may be important events in the three ethnic groups with colorectal cancer. The lower mortality rate among Ashkenazi Jews may be partially explained by their better molecular biology profile.

KW - Ashkenazi Jews

KW - Colorectal cancer

KW - Molecular epidemiology

KW - Palestinians

KW - Sephardic Jews

UR - http://www.scopus.com/inward/record.url?scp=0036737230&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdf230

DO - 10.1093/annonc/mdf230

M3 - 文章

C2 - 12196377

AN - SCOPUS:0036737230

SN - 0923-7534

VL - 13

SP - 1497

EP - 1501

JO - Annals of Oncology

JF - Annals of Oncology

IS - 9

ER -

Fighting colorectal cancer: Molecular epidemiology differences among Ashkenazi and Sephardic Jews and Palestinians

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this